CD40LG and Skin rash: In a study involving 52 melanoma patients experiencing various types of irAEs within 6 months of initiation of ICI therapy, it was found that the 8 patients who developed a skin rash exhibited elevated levels of basal serum angiopoietin-1 (Ang-1) and CD40L compared to those ICI-treated individuals who did not experience a rash (101).